Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
Exploring Personal Stem Cell Banking within Regenerative Medicine: A Conversation with Kevin Ferber, COO of American Cell Technology
As the world of healthcare continues to evolve, regenerative medicine is emerging as a cornerstone of personalized, proactive health. In line with the mission of the 2025 HEALinc Global Summit – which aims to restore whole-person health through cutting-edge technologies, mentorship and education – the potential of stem cell therapy is poised to redefine our approach to health, longevity and wellness. Founded in 2018 by Dr. Desirée Cox (MD, MPhil, PhD), the HEALinc Global Summit brings together leaders and innovators to explore the latest scientific breakthroughs in healthy longevity and regenerative medicine. This year’s Summit will be held at the Atlantis Resort in The Bahamas from April 27th – 29th, 2025. [Read more…]
Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next
-
Current Trial (Cohorts A–C): Sernova’s current cohorts are focused on testing the safety and tolerability of transplanting donor islets (from cadaveric pancreases) into Sernova’s Cell Pouch device in T1D patients.
-
Future Direction (Post-Cohort C): Next, Sernova plans to launch a new clinical trial using iPSC-derived islet-like clusters, instead of relying on donor islets. This will be in collaboration with Evotec, a leading iPSC company.
-
Why iPSCs Matter: iPSC-derived islet-like clusters offer a renewable, potentially unlimited cell source for treating T1D, overcoming the limitations of donor availability. This aligns with Sernova’s goal of developing a scalable and widely accessible solution.
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called “KGF alternative- peptide (FGFR2b agonist)” which is functionally equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025. [Read more…]
REPROCELL’s Clinical-Grade iPSCs:
Advancing Cell Therapy
In the rapidly evolving field of regenerative medicine, REPROCELL’s StemRNATM Clinical iPSCs provide a benchmark for clinical grade induced pluripotent stem cells (iPSCs). These high-quality iPSCs provide a foundation for various cell therapy programs, ensuring safety, consistency, and regulatory compliance. Our clinical iPSCs are currently being evaluated by many biopharma companies globally, are selected for regulatory filings and are IND approved. REPROCELL is a trusted partner for cell therapy developers who are seeking robust, high-quality clinical iPSC banks that meet industry standards. [Read more…]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- 18
- Next Page »